Ascelia Pharma
Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB (MFN)
Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 6 May 2024 has been appointed.
In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the members should be one representative of each of the three largest shareholders who wish to appoint such representative together with the chairman of the board of directors. The Nomination Committee shall be composed based on shareholder statistics from Euroclear Sweden AB as of the last banking day in September and other reliable shareholder information which has been provided to the company at such time.
Based on the above, the Nomination Committee in respect of the AGM that will be held in Malmö on 6 May 2024 has been established to consist of the following persons together representing approximately 22% of votes in the company:
- Jørgen Thorball, chairman of the Nomination Committee, appointed by Sunstone Life Science Ventures II K/S;
- Håkan Nelson, appointed by Niels Mengel (through own holdings and holdings via Kibgeon ApS)*;
- Lars Vedin, appointed by Spogárd Holding A/S; and
- Peter Benson, chairman of the board of directors.
* As of the last banking day in September 2023, Øresund-Healthcare Management A/S was one of the three largest shareholders in the company that had expressed a wish to appoint a member of the Nomination Committee. Øresund-Healthcare Management A/S has subsequently distributed all its shares in Ascelia Pharma AB to its shareholders, among them Niels Mengel and Kibgeon ApS.
The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2024 and on the company’s website, www.ascelia.com.
The duties of the Nomination Committee are to prepare and propose the following to the coming annual shareholders’ meeting: election of chairman at the shareholders’ meeting; election of chairman of the board of directors and other members of the board of directors; fees to the board of directors, divided between the chairman and other members, and any fees for committee work; election of auditor and fees to the auditor; and principles for appointment of the Nomination Committee.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address or alternatively via e-mail jwb@ascelia.com. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 29 February 2024, to ensure that the proposals can be considered by the Nomination Committee.
Contacts
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118
Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: jwb@ascelia.com
Tel: +46 735 179 116
This information was submitted for publication, through the agency of the contact persons set out above.
About Us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
About Orviglance (previously referred to as Mangoral)
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has been completed. Results from the Phase 3 study are not yet available.
About Oncoral
Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.